HRGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HRGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Harvard Apparatus Regenerative Technology's annualized ROCE % for the quarter that ended in Dec. 2023 was -322.71%.
The historical data trend for Harvard Apparatus Regenerative Technology's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Apparatus Regenerative Technology Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
ROCE % | Get a 7-Day Free Trial | -533.31 | -390.55 | - | - | -665.75 |
Harvard Apparatus Regenerative Technology Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
ROCE % | Get a 7-Day Free Trial | -345.07 | -570.69 | -310.79 | -199.24 | -322.71 |
Harvard Apparatus Regenerative Technology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -8.931 | / | ( ( (2.4 - 1.363) | + | (2.614 - 0.968) ) | / 2 ) | |
= | -8.931 | / | ( (1.037 | + | 1.646) | / 2 ) | |
= | -8.931 | / | 1.3415 | ||||
= | -665.75 % |
Harvard Apparatus Regenerative Technology's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Dec. 2023 ) | (Q: Sep. 2023 ) | (Q: Dec. 2023 ) | |||||
= | -7.056 | / | ( ( (3.782 - 1.055) | + | (2.614 - 0.968) ) | / 2 ) | |
= | -7.056 | / | ( ( 2.727 | + | 1.646 ) | / 2 ) | |
= | -7.056 | / | 2.1865 | ||||
= | -322.71 % |
(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Apparatus Regenerative Technology (OTCPK:HRGN) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Harvard Apparatus Regenerative Technology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Junli He | director | C/O NO.1, COUNTRY GARDEN ROAD, BEIJIAO TOWN, SHUNDE DISTRICT, FOSHAN F4 528300 |
James E. Shmerling | director | 975 JOHNSON FERRY ROAD, SUITE 450, ATLANTA GA 30342 |
Dst Capital Llc | 10 percent owner | C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746 |
Ronald J Packard | director | 2300 CORPORATE PARK DRIVE, HERNDON VA 20171 |
Jing Chen | director | C/O BIOSTAGE,INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 02110 |
Hong Yu | officer: President | C/O BIOSTAGE, INC. 84 OCTOBER HILL ROAD, HOLLISTON MA 01746 |
Damasio Joseph Luis Jr | officer: Chief Financial Officer | 14 NORFOLK AVENUE, SOUTH EASTON MA 02375 |
David Green | director, officer: See Remarks | C/O HARVARD BIOSCIENCE INC, 84 OCTOBER HILL ROAD, HOLLISTON MA 01746-1371 |
William Fodor | officer: Chief Scientific Officer | C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746 |
Peter A. Pellegrino | officer: Interim VP of Finance | C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746 |
Herman Sanchez | director | 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746 |
James Mastridge | officer: See Remarks | C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746 |
Jeffrey E Young | director | 60 WESTVIEW STREET, LEXINGTON MA 02421 |
Wei Zhang | director | C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746 |
Ting Li | director | C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746 |
From GuruFocus
By PRNewswire PRNewswire • 07-02-2022
By PRNewswire PRNewswire • 08-04-2022
By PRNewswire PRNewswire • 01-12-2023
By PRNewswire PRNewswire • 06-25-2022
By PRNewswire PRNewswire • 06-29-2022
By PRNewswire • 08-21-2023
By PRNewswire PRNewswire • 07-05-2022
By PRNewswire PRNewswire • 12-23-2022
By PRNewswire PRNewswire • 03-02-2023
By PRNewswire PRNewswire • 06-19-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.